Clostridium difficile infection after adult autologous stem cell transplantation: A multicenter study of epidemiology and risk factors

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 10, 2013, Pages 1502-1508

  Alonso, Carolyn D ^a   Dufresne, Simon F ^b   Hanna, David B ^c   Labbé, Annie Claude ^b   Treadway, Suzanne B ^d   Neofytos, Dionissios ^e   Bélanger, Sylvie ^b   Huff, Carol Ann ^e   Laverdière, Michel ^b   Marr, Kieren A ^e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Departments of Microbiology and Immunology   (Canada)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Clostridium difficile; Mucositis; NAP 1; Stem cell transplantation

Indexed keywords

CARBAPENEM DERIVATIVE; CEPHALOSPORIN; CLINDAMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METRONIDAZOLE; NITAZOXANIDE; PENICILLIN DERIVATIVE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RIFAXIMIN; RITUXIMAB; VANCOMYCIN;

ACUTE LEUKEMIA; ADULT; ANTIBIOTIC THERAPY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL STRAIN; CANCER CHEMOTHERAPY; CASE CONTROL STUDY; CHRONIC LEUKEMIA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; FEMALE; GASTROINTESTINAL MUCOSA; GRAFT RECIPIENT; HOSPITAL; HUMAN; INCIDENCE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE MYELOMA; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SURGICAL RISK;

ANTIBIOTICS; CLOSTRIDIUM DIFFICILE; MUCOSITIS; NAP-1; STEM CELL TRANSPLANTATION;

CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84884190473     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.07.022     Document Type: Article

References (37)

1. Lucado J., Gould C., Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009. Healthcare Cost and Utilization Project Statistical Brief 124 2010, Agency for Health Care Policy and Research, Rockville (MD).
2. Centers for Disease Control and Prevention Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012, 61:157-162.
3. Hall A.J., Curns A.T., McDonald L.C., et al. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 2012, 55:216-223.
4. Rupnik M., Wilcox M.H., Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009, 7:526-536.
5. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. NEngl J Med 2005, 353:2433-2441.
6. Labbé A.C., Poirier L., Maccannell D., et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 2008, 52:3180-3187.
7. Bobak D., Arfons L.M., Creger R.J., Lazarus H.M. Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm?. Bone Marrow Transplant 2008, 42:705-713.
8. Alonso C.D., Treadway S.B., Hanna D.B., et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012, 54:1053-1063.
9. Chopra T., Chandrasekar P., Salimnia H., et al. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant 2011, 25:E82-E87.
10. Bilgrami S., Feingold J.M., Dorsky D., et al. Incidence and outcome ofClostridium difficile infection following autologous peripheral bloodstem cell transplantation. Bone Marrow Transplant 1999, 23:1039-1042.
11. Harris P.A., Taylor R., Thielke R., et al. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. JBiomed Inform 2009, 42:377-381.
12. Bartlett J.G. Clostridium difficile: progress and challenges. Ann NY Acad Sci 2010, 1213:62-69.
13. Bouza E., Burillo A., Munoz P. Antimicrobial therapy of Clostridium difficile-associated diarrhea. Med Clin North Am 2006, 90:1141-1163.
14. Brodsky R.A., Chen A.R., Dorr D., et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood 2010, 115:2136-2141.
15. DeZern A.E., Petri M., Drachman D.B., et al. High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. Medicine (Baltimore) 2011, 90:89-98.
16. Cancer Therapy Evaluation Group, National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). Available from: Accessed January 20, 2012. http://ctep.cancer.gov/protocolDevelopment/.
17. De Pauw B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
18. Borek A.P., Aird D.Z., Carroll K.C. Frequency of sample submission for optimal utilization of the cell culture cytotoxicity assay for detection of Clostridium difficile toxin. JClin Microbiol 2005, 43:2994-2995.
19. Song X., Bartlett J.G., Speck K., et al. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 2008, 29:823-828.
20. Vittinghoff E., Glidden D.V., Shiboski S.C., McCulloch C.E. Regression methods in biostatistics: linear, logistic, survival, and repeated measures models 2005, Springer, New York.
21. Kamboj M., Son C., Cantu S., et al. Hospital-onset Clostridium difficile infection rates in persons with cancer or hematopoietic stem cell transplant: a C3IC Network report. Infect Control Hosp Epidemiol 2012, 33:1162-1165.
22. Arango J.I., Restrepo A., Schneider D.L., et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 2006, 37:517-521.
23. Avery R., Pohlman B., Adal K., et al. High prevalence of diarrhea but infrequency of documented Clostridium difficile in autologous peripheral blood progenitor cell transplant recipients. Bone Marrow Transplant 2000, 25:67-69.
24. Trifilio S.M., Pi J., Mehta J. Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation. Biol Blood Marrow Transplant 2012, 19:405-409.
25. Barton T., Collis T., Stadtmauer E., Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 2001, 32:391-395.
26. Neofytos D., Kobayashi K., Alonso C.D., et al. Epidemiology, risk factors, and outcomes of Clostridium difficile infection in kidney transplant recipients. Transpl Infect Dis 2012, 134-141.
27. Loo V.G., Bourgault A.M., Poirier L., et al. Host and pathogen factors for Clostridium difficile infection and colonization. NEngl J Med 2011, 365:1693-1703.
28. Raza S., Baig M.A., Russell H., et al. Clostridium difficile infection following chemotherapy. Recent Pat Antiinfect Drug Discov 2010, 5:1-9.
29. Taur Y., Xavier J.B., Lipuma L., et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012, 55:905-914.
30. Garey K.W., Dao-Tran T.K., Jiang Z.D., et al. Aclinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. JHosp Infect 2008, 70:142-147.
31. Bauer M.P., Notermans D.W., van Benthem B.H., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377:63-73.
32. Kyne L., Warny M., Qamar A., Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. NEngl J Med 2000, 342:390-397.
33. Kyne L., Warny M., Qamar A., Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357:189-193.
34. El Feghaly R.E., Stauber J.L., Deych E., et al. Markers of intestinalinflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis 2013, 56:1713-1721.
35. Nomura K., Fujimoto Y., Yamashita M., et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol 2009, 44:74-78.
36. Dubberke E.R., Reske K.A., Srivastava A., et al. Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant 2010, 24:192-198.
37. Willems L., Porcher R., Lafaurie M., et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2012, 18:1295-1301.